A Phase 2 interventional study of filgotinib and Placebo Oral Tablet in Psoriatic Arthritis, sponsored by Galapagos NV. Completed at 25 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-23.
Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Arthritis, Psoriatic with a site in Ukraine — none open to participants now, 6 under way, 2 of them phase 3. Arthritis, Psoriatic · Ukraine.
Among the 22 studies in Arthritis, Psoriatic with a site in Ukraine, this one is the 17th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2017, is one of 6 in phase 2, and was the 7th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →None of the 22 studies in Arthritis, Psoriatic with a site in Ukraine is open now. The open studies under Arthritis, Psoriatic, anywhere →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 12 · Phase 4 2
First in 2007; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is close to the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 389 across the 20 interventional studies, 11,000 across the 2 observational. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 3 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis, Psoriatic with a site in Ukraine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07486960Merck Sharp & Dohme LLCStudy to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) | 2027-02-17 |
| NCT04929210Janssen Research & Development, LLCA Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Arthritis, Psoriatic with a site in Ukraine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with moderately to severely active Psoriatic Arthritis (PsA) who have an inadequate response or are intolerant to conventional disease-modifying therapy. A total of approximately 124 subjects will be randomized to one of 2 treatment arms in a 1:1 ratio: oral filgotinib tablets q.d. or matching placebo tablets q.d. The Screening visit will occur within 28 days before study drug administration. At Day 1 (Baseline), eligible subjects will be randomized to treatment for a duration of 16 weeks. The study is concluded with a Follow-up period lasting until 4 weeks after the last dose. Consequently, each subject will stay in the study for a maximum of 24 weeks (from Screening visit to Follow-up visit).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: filgotinib
Drug: Placebo Oral Tablet
one filgotinib oral tablet q.d.
one placebo oral tablet q.d.
Percentage of subjects who have reached ACR20 response as compared to placebo
To assess the effect of filogotinib on PsA as assessed by ACR20 in PsA patients
Time frame: Week 16
Assessment of minimal disease activity (MDA) in filgotinib treated subjects as compared to placebo
To assess the effect of filogotinib on MDA in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Percentage of subjects who have reached ACR50 response as compared to placebo
To assess the effect of filogotinib on PsA as assessed by ACR50 in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Percentage of subjects who have reached ACR70 response as compared to placebo
To assess the effect of filogotinib on PsA as assessed by ACR70 in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Percentage of subjects achieving DAS28(CRP) score as compared to placebo
To assess the effect of filogotinib on PsA as assessed by DAS28 (CRP) in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Percentage of subjects achieving SDAI response as compared to placebo
To assess the effect of filogotinib on PsA as assessed by SDAI response in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Percentage of subjects achieving CDAI response as compared to placebo
To assess the effect of filgotinib on PsA as assessed by CDAI response in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Percentage of subjects achieving EULAR response as compared to placebo
To assess the effect of filogotinib on PsA as assessed by EULAR response in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Assessment of psoriatic arthritis response criteria (PsARC) as compared to placebo
To assess the effect of filogotinib on PsARC in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Assessment of physician's and patient's global assessment of disease activity as compared to placebo
To assess the effect of filogotinib on physician's and patient's global assessment of disease activity in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Assessment of patient's global assessment of PsA pain intensity in filgotinib treated subjects as compared to placebo
To assess the effect of filogotinib on on PsA pain intensity in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Assessment of joints for tenderness (68) and swelling (66) in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on joint tenderness and swelling in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Assessment of CRP in filgotinib treated subjects as compared to placebo
To assess the effect of filogotinib on CRP in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Psoriasis as assessed by PASI in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on PASI in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Psoriasis as assessed by PASI50 in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on PASI50 in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Psoriasis as assessed by PASI75 in filgotinib treated subjects as compared to placebo
To assess the affect of filgotinib on PASI75 in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Psoriasis as assessed by PASI90 in filgotinib treated subjects as compared to placebo
To assess the affect of filgotinib on PASI90 in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Psoriasis as assessed by PASI100 in filgotinib treated subjects as compared to placebo
To assess the affect of filgotinib on PASI100 in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Physician's and patient's global assessment of psoriasis in filgotinib treated subjects as compared to placebo
To assess the affect of filgotinib on Physician's and patient's global assessment of psoriasis in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Assessment of mNAPSI in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on mNAPSI in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Assessment of pruritis NRS in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on NRS in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Enthesitis as assessed by SPARCC enthesitis index in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on SPARCC enthesitis index in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Dactilytis as assessed by LDI in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on Dactilytis in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Physical function as assessed by HAQ-DI in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on physical function in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
FACIT-Fatigue scale in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on FACIT-Fatigue scale in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Assessment of SF-36 in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on SF-36 in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Assessment of Psoriatic Arthritis Impact of Disease Questionnaire (PsAID) in filgotinib treated subjects as compared to placebo
To assess the effect of filgotinib on PsAID in PsA patients
Time frame: At each visit from screening until the final follow up visit (week 20)
Difference between the number of filgotinib treated subjects and placebo subjects in the number of adverse events
To evaluation safety and tolerability of filgotinib in PsA patients
Time frame: From screening until the final follow up visit (week 20)
Difference between the number of filgotinib treated subjects and placebo subjects with abnormal clinical laboratory evaluations
To evaluation safety and tolerability of filgotinib in PsA patients
Time frame: From screening until the final follow up visit (week 20)
Difference between the number of filgotinib treated subjects and placebo subjects with abnormal vital signs
To evaluation safety and tolerability of filgotinib in PsA patients
Time frame: From screening until the final follow up visit (week 20)
Difference between the number of filgotinib treated subjects and placebo subjects with abnormal physical examination
To evaluation safety and tolerability of filgotinib in PsA patients
Time frame: From screening until the final follow up visit (week 20)
Difference between the number of filgotinib treated subjects and placebo subjects with abnormal ECG
To evaluation safety and tolerability of filgotinib in PsA patients
Time frame: From screening until the final follow up visit (week 20)
Difference between the number of filgotinib treated subjects and placebo subjects with abnormal radiographic assessment
To evaluation safety and tolerability of filgotinib in PsA patients
Time frame: From screening until the final follow up visit (week 20)
Plan to share: Undecided
Ran from Mar 2017 to primary completion in Mar 2018, 12 months.
Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634